First, there is limited information on laboratory measurements, particularly urine albumin, hepatic enzymes, which is the main reason why we decided to define eligibility only on the basis of inclusion criteria; this, in turns, could have led to an overestimation of CVOT eligibility for the general population of patients with T2D. This evidence concerns the gene ALB and type 2 diabetes mellitus.